ArticleFrontiers in medicine2022
Blood-Cell-Based Inflammatory Markers as a Useful Tool for Early Diagnosis in Colorectal Cancer.
Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Paeonol-Loaded PLGA Nanoparticles Attenuate DMH-Induced Colorectal Carcinogenesis-Associated Oxidative Stress, Inflammation, and Cellular Dysregulation via Modulation of NRF2/HO-1 Signaling in Rats.International journal of molecular sciences · 2026Article
- Baseline Red Blood Cell Distribution Width as a Prognostic Marker in High-Risk Resected Cutaneous Melanoma.Journal of clinical medicine · 2026Article
- The predictive value of complete blood count and the systemic immune-inflammation index (SII) for diagnosing malignancy in patients undergoing colonoscopy.BMC primary care · 2026Article
- A screening model for advanced colorectal neoplasia based on tumor markers and inflammatory indices: a retrospective study with an online risk calculator.Frontiers in oncology · 2026Article
- Interpretable Machine Learning Models Based on Blood Cell-Derived Inflammatory Indices for Identifying Colorectal Neoplasia: A Retrospective Study.Journal of inflammation research · 2026Article
- Taxonomic Profiling of Systemic Inflammatory Parameters as Predictors of Tumor Progression in Primary Colorectal Cancer.Journal of clinical medicine · 2025Article
- Assessment of Adipokine and Inflammation Biomarkers with Cancer Risk among Chinese Men: A Prospective Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Colorectal Cancer-One Disease, Two Fires: Distinct Inflammatory Landscapes in Colon and Rectal Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Comparative Prognostic Role of PLR and NLR in Colon Cancer: A Retrospective Analysis of Preoperative Inflammatory Markers.Medicina (Kaunas, Lithuania) · 2025Observational
- Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study.Medical sciences (Basel, Switzerland) · 2025Observational
- Assessment of Common Hematologic Parameters and Novel Hematologic Ratios for Predicting Piroplasmosis Infection in Horses.Animals : an open access journal from MDPI · 2025Article
- Prognostic value of combined NP and LHb index with absolute monocyte count in colorectal cancer patients.Scientific reports · 2025Article
- Value of brief hematological characteristics in differentiating carcinoembryonic-antigen-negative colorectal cancer from benign colorectal diseases.World journal of gastrointestinal surgery · 2025Article
- Complete blood counts as potential risk factors of early dissemination to liver and lungs in resected colorectal cancer: a retrospective cohort study.International journal of colorectal disease · 2025Article
- NOS2/ARG1 axis and immune cell ratios as promising prognostic and predictive biomarkers for Cetuximab combined with chemotherapy in wt-KRAS human colorectal cancer.Frontiers in immunology · 2025Article
- Combined CA125, NSE, and multiple inflammatory indices for diagnosis of oral squamous cell carcinoma.Frontiers in oncology · 2025Article
- Clinical diagnostic value of methylated SEPT9 combined with NLR, PLR and LMR in colorectal cancer.BMC gastroenterology · 2024Article
- [Genetic drivers for inflammatory protein markers in colorectal cancer: a Mendelian randomization approach to clinical prognosis study].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies.Medicina (Kaunas, Lithuania) · 2024Article
- Editorial: Insights in gastroenterology: 2022.Frontiers in medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation seems to be involved in the pathogenetic pathways of colorectal cancer (CRC). Analytical markers that reflect the inflammatory status, such as neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) or systemic immune-inflammation index (SII), have been proposed as tools for the prognosis of CRC. Nevertheless, their use for diagnosis has been scarcely investigated. Aims: To analyze the ability of these markers and of a new marker combining SII and hemoglobin concentration, named NP/LHb = [neutrophils x platelets]/[lymphocytes x hemoglobin], as tools for CRC diagnosis. Furthermore, we studied their association with CRC-related variables. Methods: Case-control study including 214 CRC patients and 214 controls without CRC, matched by age (±5 years) and sex. We collected demographic, CRC-related and laboratory variables to calculate NLR, PLR, SII, and NP/LHb. In the case group, the laboratory variables were collected at two different period times, 6 months (IQR 4-8) before the CRC diagnosis and at the time of the diagnosis. ROC analysis was performed to evaluate the discriminatory accuracy of each index and we calculated Se, Sp, PPV, NPV, and OR to identify the diagnostic performance of each positive marker. Results: NP/LHb showed high Sp (92.06%) and PPV (87.50%) to diagnose patients with CRC. This index exhibited an OR of 14.52 (8.26-25.52) and the best area under the curve (AUC: 0.78) for a positive CRC diagnosis. We found significant differences in all indices according to the presence of CRC, observing the highest values in CRC patients at time of diagnosis, in comparison with the analysis performed in the previous months to diagnosis or with control patients. There were significant differences in all ratios according to TNM stages ( Conclusions: Systemic inflammatory cell ratios (especially NP/LHb) change over time with the development of CRC, so they could be useful in its early diagnosis. We suggest that they could be routinely measured in patients with suspicion of CRC, to identify those ones with a higher risk of cancer, considering the high positive predictive value they have shown in our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.